Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia Article Swipe
Maximilian Fleischmann
,
Madlen Jentzsch
,
Annamaria Brioli
,
Florian Eisele
,
Jochen J. Frietsch
,
Farina Eigendorff
,
Romy Tober
,
Karin G. Schrenk
,
Jakob Hammersen
,
Olaposi Yomade
,
Inken Hilgendorf
,
Andreas Hochhaus
,
Sebastian Scholl
,
Ulf Schnetzke
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1007/s00277-024-06048-5
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1007/s00277-024-06048-5
The combination of venetoclax with hypomethylating agents is currently the standard of care for elderly patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy. Despite its favorable efficacy, clinical use is often associated with post-remission cytopenia, frequently necessitating treatment delays and dose modifications. This study aims to evaluate the efficacy and safety of shortened venetoclax treatment durations. A multicenter analysis was conducted involving 20 adult AML patients receiving venetoclax (7 or 14 days with 9 and 11 patients, respectively) combined with 5-azacitidine (5–7 days) between 2021 and 2024. The cohort included patients from four German academic centers all treated in first line. Outcome measures included bone marrow response, transfusion dependence, overall survival (OS) and progression-free survival (PFS). Median age was 73.5 years, with 70% of patients having secondary AML. Adverse molecular risk was observed in 75% of patients. The overall response rate (ORR) was 100%, with a composite complete remission rate of 78%. No significant differences in response rates were observed between the 7-day and 14-day venetoclax regimens. Median OS for the cohort was 15 months. Infection-related complications were observed in 55% of patients, with severe sepsis in 20% of cases. In this cohort, shortened venetoclax regimens demonstrated efficacy comparable to standard treatment protocols, with a potential reduction in hematologic toxicity. These findings support the individualization of treatment regimens to optimize clinical outcomes while potentially minimizing adverse effects.
Related Topics
Concepts
Venetoclax
Medicine
Azacitidine
Cytopenia
Internal medicine
Hypomethylating agent
Myeloid leukemia
Adverse effect
Oncology
Cohort
Hematology
Leukemia
Bone marrow
Chronic lymphocytic leukemia
DNA methylation
Chemistry
Biochemistry
Gene expression
Gene
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1007/s00277-024-06048-5
- OA Status
- hybrid
- Cited By
- 1
- References
- 35
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4403778679
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4403778679Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1007/s00277-024-06048-5Digital Object Identifier
- Title
-
Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemiaWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2024Year of publication
- Publication date
-
2024-10-25Full publication date if available
- Authors
-
Maximilian Fleischmann, Madlen Jentzsch, Annamaria Brioli, Florian Eisele, Jochen J. Frietsch, Farina Eigendorff, Romy Tober, Karin G. Schrenk, Jakob Hammersen, Olaposi Yomade, Inken Hilgendorf, Andreas Hochhaus, Sebastian Scholl, Ulf SchnetzkeList of authors in order
- Landing page
-
https://doi.org/10.1007/s00277-024-06048-5Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
hybridOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1007/s00277-024-06048-5Direct OA link when available
- Concepts
-
Venetoclax, Medicine, Azacitidine, Cytopenia, Internal medicine, Hypomethylating agent, Myeloid leukemia, Adverse effect, Oncology, Cohort, Hematology, Leukemia, Bone marrow, Chronic lymphocytic leukemia, DNA methylation, Chemistry, Biochemistry, Gene expression, GeneTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
1Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 1Per-year citation counts (last 5 years)
- References (count)
-
35Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4403778679 |
|---|---|
| doi | https://doi.org/10.1007/s00277-024-06048-5 |
| ids.doi | https://doi.org/10.1007/s00277-024-06048-5 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/39453477 |
| ids.openalex | https://openalex.org/W4403778679 |
| fwci | 0.96619675 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D006801 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Humans |
| mesh[1].qualifier_ui | Q000188 |
| mesh[1].descriptor_ui | D015470 |
| mesh[1].is_major_topic | True |
| mesh[1].qualifier_name | drug therapy |
| mesh[1].descriptor_name | Leukemia, Myeloid, Acute |
| mesh[2].qualifier_ui | Q000401 |
| mesh[2].descriptor_ui | D015470 |
| mesh[2].is_major_topic | True |
| mesh[2].qualifier_name | mortality |
| mesh[2].descriptor_name | Leukemia, Myeloid, Acute |
| mesh[3].qualifier_ui | |
| mesh[3].descriptor_ui | D000368 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | |
| mesh[3].descriptor_name | Aged |
| mesh[4].qualifier_ui | |
| mesh[4].descriptor_ui | D008297 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | |
| mesh[4].descriptor_name | Male |
| mesh[5].qualifier_ui | |
| mesh[5].descriptor_ui | D005260 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | |
| mesh[5].descriptor_name | Female |
| mesh[6].qualifier_ui | Q000008 |
| mesh[6].descriptor_ui | D000971 |
| mesh[6].is_major_topic | True |
| mesh[6].qualifier_name | administration & dosage |
| mesh[6].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[7].qualifier_ui | Q000009 |
| mesh[7].descriptor_ui | D000971 |
| mesh[7].is_major_topic | True |
| mesh[7].qualifier_name | adverse effects |
| mesh[7].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[8].qualifier_ui | Q000627 |
| mesh[8].descriptor_ui | D000971 |
| mesh[8].is_major_topic | True |
| mesh[8].qualifier_name | therapeutic use |
| mesh[8].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[9].qualifier_ui | Q000008 |
| mesh[9].descriptor_ui | D001374 |
| mesh[9].is_major_topic | True |
| mesh[9].qualifier_name | administration & dosage |
| mesh[9].descriptor_name | Azacitidine |
| mesh[10].qualifier_ui | Q000009 |
| mesh[10].descriptor_ui | D001374 |
| mesh[10].is_major_topic | True |
| mesh[10].qualifier_name | adverse effects |
| mesh[10].descriptor_name | Azacitidine |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D008875 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | Middle Aged |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D000369 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Aged, 80 and over |
| mesh[13].qualifier_ui | Q000008 |
| mesh[13].descriptor_ui | D019086 |
| mesh[13].is_major_topic | True |
| mesh[13].qualifier_name | administration & dosage |
| mesh[13].descriptor_name | Bridged Bicyclo Compounds, Heterocyclic |
| mesh[14].qualifier_ui | Q000009 |
| mesh[14].descriptor_ui | D019086 |
| mesh[14].is_major_topic | True |
| mesh[14].qualifier_name | adverse effects |
| mesh[14].descriptor_name | Bridged Bicyclo Compounds, Heterocyclic |
| mesh[15].qualifier_ui | Q000008 |
| mesh[15].descriptor_ui | D013449 |
| mesh[15].is_major_topic | True |
| mesh[15].qualifier_name | administration & dosage |
| mesh[15].descriptor_name | Sulfonamides |
| mesh[16].qualifier_ui | Q000009 |
| mesh[16].descriptor_ui | D013449 |
| mesh[16].is_major_topic | True |
| mesh[16].qualifier_name | adverse effects |
| mesh[16].descriptor_name | Sulfonamides |
| mesh[17].qualifier_ui | |
| mesh[17].descriptor_ui | D012189 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | |
| mesh[17].descriptor_name | Retrospective Studies |
| mesh[18].qualifier_ui | |
| mesh[18].descriptor_ui | D015996 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | |
| mesh[18].descriptor_name | Survival Rate |
| mesh[19].qualifier_ui | |
| mesh[19].descriptor_ui | D006801 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | |
| mesh[19].descriptor_name | Humans |
| mesh[20].qualifier_ui | Q000627 |
| mesh[20].descriptor_ui | D019086 |
| mesh[20].is_major_topic | True |
| mesh[20].qualifier_name | therapeutic use |
| mesh[20].descriptor_name | Bridged Bicyclo Compounds, Heterocyclic |
| mesh[21].qualifier_ui | Q000008 |
| mesh[21].descriptor_ui | D019086 |
| mesh[21].is_major_topic | True |
| mesh[21].qualifier_name | administration & dosage |
| mesh[21].descriptor_name | Bridged Bicyclo Compounds, Heterocyclic |
| mesh[22].qualifier_ui | Q000009 |
| mesh[22].descriptor_ui | D019086 |
| mesh[22].is_major_topic | True |
| mesh[22].qualifier_name | adverse effects |
| mesh[22].descriptor_name | Bridged Bicyclo Compounds, Heterocyclic |
| mesh[23].qualifier_ui | Q000008 |
| mesh[23].descriptor_ui | D013449 |
| mesh[23].is_major_topic | True |
| mesh[23].qualifier_name | administration & dosage |
| mesh[23].descriptor_name | Sulfonamides |
| mesh[24].qualifier_ui | Q000627 |
| mesh[24].descriptor_ui | D013449 |
| mesh[24].is_major_topic | True |
| mesh[24].qualifier_name | therapeutic use |
| mesh[24].descriptor_name | Sulfonamides |
| mesh[25].qualifier_ui | Q000009 |
| mesh[25].descriptor_ui | D013449 |
| mesh[25].is_major_topic | True |
| mesh[25].qualifier_name | adverse effects |
| mesh[25].descriptor_name | Sulfonamides |
| mesh[26].qualifier_ui | Q000188 |
| mesh[26].descriptor_ui | D015470 |
| mesh[26].is_major_topic | True |
| mesh[26].qualifier_name | drug therapy |
| mesh[26].descriptor_name | Leukemia, Myeloid, Acute |
| mesh[27].qualifier_ui | Q000401 |
| mesh[27].descriptor_ui | D015470 |
| mesh[27].is_major_topic | True |
| mesh[27].qualifier_name | mortality |
| mesh[27].descriptor_name | Leukemia, Myeloid, Acute |
| mesh[28].qualifier_ui | |
| mesh[28].descriptor_ui | D000368 |
| mesh[28].is_major_topic | False |
| mesh[28].qualifier_name | |
| mesh[28].descriptor_name | Aged |
| mesh[29].qualifier_ui | |
| mesh[29].descriptor_ui | D008297 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | |
| mesh[29].descriptor_name | Male |
| mesh[30].qualifier_ui | |
| mesh[30].descriptor_ui | D005260 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | |
| mesh[30].descriptor_name | Female |
| mesh[31].qualifier_ui | Q000008 |
| mesh[31].descriptor_ui | D001374 |
| mesh[31].is_major_topic | True |
| mesh[31].qualifier_name | administration & dosage |
| mesh[31].descriptor_name | Azacitidine |
| mesh[32].qualifier_ui | Q000627 |
| mesh[32].descriptor_ui | D001374 |
| mesh[32].is_major_topic | True |
| mesh[32].qualifier_name | therapeutic use |
| mesh[32].descriptor_name | Azacitidine |
| mesh[33].qualifier_ui | Q000009 |
| mesh[33].descriptor_ui | D001374 |
| mesh[33].is_major_topic | True |
| mesh[33].qualifier_name | adverse effects |
| mesh[33].descriptor_name | Azacitidine |
| mesh[34].qualifier_ui | Q000627 |
| mesh[34].descriptor_ui | D000971 |
| mesh[34].is_major_topic | True |
| mesh[34].qualifier_name | therapeutic use |
| mesh[34].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[35].qualifier_ui | Q000009 |
| mesh[35].descriptor_ui | D000971 |
| mesh[35].is_major_topic | True |
| mesh[35].qualifier_name | adverse effects |
| mesh[35].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[36].qualifier_ui | |
| mesh[36].descriptor_ui | D000369 |
| mesh[36].is_major_topic | False |
| mesh[36].qualifier_name | |
| mesh[36].descriptor_name | Aged, 80 and over |
| mesh[37].qualifier_ui | |
| mesh[37].descriptor_ui | D008875 |
| mesh[37].is_major_topic | False |
| mesh[37].qualifier_name | |
| mesh[37].descriptor_name | Middle Aged |
| mesh[38].qualifier_ui | |
| mesh[38].descriptor_ui | D004334 |
| mesh[38].is_major_topic | False |
| mesh[38].qualifier_name | |
| mesh[38].descriptor_name | Drug Administration Schedule |
| mesh[39].qualifier_ui | |
| mesh[39].descriptor_ui | D012189 |
| mesh[39].is_major_topic | False |
| mesh[39].qualifier_name | |
| mesh[39].descriptor_name | Retrospective Studies |
| mesh[40].qualifier_ui | |
| mesh[40].descriptor_ui | D006801 |
| mesh[40].is_major_topic | False |
| mesh[40].qualifier_name | |
| mesh[40].descriptor_name | Humans |
| mesh[41].qualifier_ui | Q000627 |
| mesh[41].descriptor_ui | D019086 |
| mesh[41].is_major_topic | True |
| mesh[41].qualifier_name | therapeutic use |
| mesh[41].descriptor_name | Bridged Bicyclo Compounds, Heterocyclic |
| mesh[42].qualifier_ui | Q000008 |
| mesh[42].descriptor_ui | D019086 |
| mesh[42].is_major_topic | True |
| mesh[42].qualifier_name | administration & dosage |
| mesh[42].descriptor_name | Bridged Bicyclo Compounds, Heterocyclic |
| mesh[43].qualifier_ui | Q000009 |
| mesh[43].descriptor_ui | D019086 |
| mesh[43].is_major_topic | True |
| mesh[43].qualifier_name | adverse effects |
| mesh[43].descriptor_name | Bridged Bicyclo Compounds, Heterocyclic |
| mesh[44].qualifier_ui | Q000008 |
| mesh[44].descriptor_ui | D013449 |
| mesh[44].is_major_topic | True |
| mesh[44].qualifier_name | administration & dosage |
| mesh[44].descriptor_name | Sulfonamides |
| mesh[45].qualifier_ui | Q000627 |
| mesh[45].descriptor_ui | D013449 |
| mesh[45].is_major_topic | True |
| mesh[45].qualifier_name | therapeutic use |
| mesh[45].descriptor_name | Sulfonamides |
| mesh[46].qualifier_ui | Q000009 |
| mesh[46].descriptor_ui | D013449 |
| mesh[46].is_major_topic | True |
| mesh[46].qualifier_name | adverse effects |
| mesh[46].descriptor_name | Sulfonamides |
| mesh[47].qualifier_ui | Q000188 |
| mesh[47].descriptor_ui | D015470 |
| mesh[47].is_major_topic | True |
| mesh[47].qualifier_name | drug therapy |
| mesh[47].descriptor_name | Leukemia, Myeloid, Acute |
| mesh[48].qualifier_ui | Q000401 |
| mesh[48].descriptor_ui | D015470 |
| mesh[48].is_major_topic | True |
| mesh[48].qualifier_name | mortality |
| mesh[48].descriptor_name | Leukemia, Myeloid, Acute |
| mesh[49].qualifier_ui | |
| mesh[49].descriptor_ui | D000368 |
| mesh[49].is_major_topic | False |
| mesh[49].qualifier_name | |
| mesh[49].descriptor_name | Aged |
| type | article |
| title | Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia |
| biblio.issue | 1 |
| biblio.volume | 104 |
| biblio.last_page | 294 |
| biblio.first_page | 285 |
| grants[0].funder | https://openalex.org/F4320313941 |
| grants[0].award_id | |
| grants[0].funder_display_name | Friedrich-Schiller-Universität Jena |
| topics[0].id | https://openalex.org/T10309 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2720 |
| topics[0].subfield.display_name | Hematology |
| topics[0].display_name | Acute Myeloid Leukemia Research |
| topics[1].id | https://openalex.org/T12172 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9927999973297119 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2730 |
| topics[1].subfield.display_name | Oncology |
| topics[1].display_name | Neutropenia and Cancer Infections |
| topics[2].id | https://openalex.org/T10345 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9898999929428101 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2720 |
| topics[2].subfield.display_name | Hematology |
| topics[2].display_name | Hematopoietic Stem Cell Transplantation |
| funders[0].id | https://openalex.org/F4320313941 |
| funders[0].ror | https://ror.org/05qpz1x62 |
| funders[0].display_name | Friedrich-Schiller-Universität Jena |
| is_xpac | False |
| apc_list.value | 3390 |
| apc_list.currency | EUR |
| apc_list.value_usd | 4390 |
| apc_paid.value | 3390 |
| apc_paid.currency | EUR |
| apc_paid.value_usd | 4390 |
| concepts[0].id | https://openalex.org/C2779675984 |
| concepts[0].level | 4 |
| concepts[0].score | 0.9364911317825317 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q23671272 |
| concepts[0].display_name | Venetoclax |
| concepts[1].id | https://openalex.org/C71924100 |
| concepts[1].level | 0 |
| concepts[1].score | 0.7713533639907837 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[1].display_name | Medicine |
| concepts[2].id | https://openalex.org/C2776239401 |
| concepts[2].level | 5 |
| concepts[2].score | 0.6704093813896179 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q416451 |
| concepts[2].display_name | Azacitidine |
| concepts[3].id | https://openalex.org/C2780366003 |
| concepts[3].level | 3 |
| concepts[3].score | 0.6696615219116211 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q246147 |
| concepts[3].display_name | Cytopenia |
| concepts[4].id | https://openalex.org/C126322002 |
| concepts[4].level | 1 |
| concepts[4].score | 0.6662489175796509 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[4].display_name | Internal medicine |
| concepts[5].id | https://openalex.org/C2776012956 |
| concepts[5].level | 5 |
| concepts[5].score | 0.5874698162078857 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q17125294 |
| concepts[5].display_name | Hypomethylating agent |
| concepts[6].id | https://openalex.org/C2778729363 |
| concepts[6].level | 2 |
| concepts[6].score | 0.5359291434288025 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q11688946 |
| concepts[6].display_name | Myeloid leukemia |
| concepts[7].id | https://openalex.org/C197934379 |
| concepts[7].level | 2 |
| concepts[7].score | 0.49539101123809814 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q2047938 |
| concepts[7].display_name | Adverse effect |
| concepts[8].id | https://openalex.org/C143998085 |
| concepts[8].level | 1 |
| concepts[8].score | 0.4773178994655609 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[8].display_name | Oncology |
| concepts[9].id | https://openalex.org/C72563966 |
| concepts[9].level | 2 |
| concepts[9].score | 0.45399317145347595 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q1303415 |
| concepts[9].display_name | Cohort |
| concepts[10].id | https://openalex.org/C194409129 |
| concepts[10].level | 2 |
| concepts[10].score | 0.4378882944583893 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q103824 |
| concepts[10].display_name | Hematology |
| concepts[11].id | https://openalex.org/C2778461978 |
| concepts[11].level | 2 |
| concepts[11].score | 0.36971813440322876 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q29496 |
| concepts[11].display_name | Leukemia |
| concepts[12].id | https://openalex.org/C2780007613 |
| concepts[12].level | 2 |
| concepts[12].score | 0.2614392042160034 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q546523 |
| concepts[12].display_name | Bone marrow |
| concepts[13].id | https://openalex.org/C2777938653 |
| concepts[13].level | 3 |
| concepts[13].score | 0.09328341484069824 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q1088156 |
| concepts[13].display_name | Chronic lymphocytic leukemia |
| concepts[14].id | https://openalex.org/C190727270 |
| concepts[14].level | 4 |
| concepts[14].score | 0.0 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q874745 |
| concepts[14].display_name | DNA methylation |
| concepts[15].id | https://openalex.org/C185592680 |
| concepts[15].level | 0 |
| concepts[15].score | 0.0 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q2329 |
| concepts[15].display_name | Chemistry |
| concepts[16].id | https://openalex.org/C55493867 |
| concepts[16].level | 1 |
| concepts[16].score | 0.0 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q7094 |
| concepts[16].display_name | Biochemistry |
| concepts[17].id | https://openalex.org/C150194340 |
| concepts[17].level | 3 |
| concepts[17].score | 0.0 |
| concepts[17].wikidata | https://www.wikidata.org/wiki/Q26972 |
| concepts[17].display_name | Gene expression |
| concepts[18].id | https://openalex.org/C104317684 |
| concepts[18].level | 2 |
| concepts[18].score | 0.0 |
| concepts[18].wikidata | https://www.wikidata.org/wiki/Q7187 |
| concepts[18].display_name | Gene |
| keywords[0].id | https://openalex.org/keywords/venetoclax |
| keywords[0].score | 0.9364911317825317 |
| keywords[0].display_name | Venetoclax |
| keywords[1].id | https://openalex.org/keywords/medicine |
| keywords[1].score | 0.7713533639907837 |
| keywords[1].display_name | Medicine |
| keywords[2].id | https://openalex.org/keywords/azacitidine |
| keywords[2].score | 0.6704093813896179 |
| keywords[2].display_name | Azacitidine |
| keywords[3].id | https://openalex.org/keywords/cytopenia |
| keywords[3].score | 0.6696615219116211 |
| keywords[3].display_name | Cytopenia |
| keywords[4].id | https://openalex.org/keywords/internal-medicine |
| keywords[4].score | 0.6662489175796509 |
| keywords[4].display_name | Internal medicine |
| keywords[5].id | https://openalex.org/keywords/hypomethylating-agent |
| keywords[5].score | 0.5874698162078857 |
| keywords[5].display_name | Hypomethylating agent |
| keywords[6].id | https://openalex.org/keywords/myeloid-leukemia |
| keywords[6].score | 0.5359291434288025 |
| keywords[6].display_name | Myeloid leukemia |
| keywords[7].id | https://openalex.org/keywords/adverse-effect |
| keywords[7].score | 0.49539101123809814 |
| keywords[7].display_name | Adverse effect |
| keywords[8].id | https://openalex.org/keywords/oncology |
| keywords[8].score | 0.4773178994655609 |
| keywords[8].display_name | Oncology |
| keywords[9].id | https://openalex.org/keywords/cohort |
| keywords[9].score | 0.45399317145347595 |
| keywords[9].display_name | Cohort |
| keywords[10].id | https://openalex.org/keywords/hematology |
| keywords[10].score | 0.4378882944583893 |
| keywords[10].display_name | Hematology |
| keywords[11].id | https://openalex.org/keywords/leukemia |
| keywords[11].score | 0.36971813440322876 |
| keywords[11].display_name | Leukemia |
| keywords[12].id | https://openalex.org/keywords/bone-marrow |
| keywords[12].score | 0.2614392042160034 |
| keywords[12].display_name | Bone marrow |
| keywords[13].id | https://openalex.org/keywords/chronic-lymphocytic-leukemia |
| keywords[13].score | 0.09328341484069824 |
| keywords[13].display_name | Chronic lymphocytic leukemia |
| language | en |
| locations[0].id | doi:10.1007/s00277-024-06048-5 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S163204731 |
| locations[0].source.issn | 0939-5555, 1432-0584 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 0939-5555 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Annals of Hematology |
| locations[0].source.host_organization | https://openalex.org/P4310319900 |
| locations[0].source.host_organization_name | Springer Science+Business Media |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310319900 |
| locations[0].license | cc-by |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Annals of Hematology |
| locations[0].landing_page_url | https://doi.org/10.1007/s00277-024-06048-5 |
| locations[1].id | pmid:39453477 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Annals of hematology |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/39453477 |
| locations[2].id | pmh:oai:pubmedcentral.nih.gov:11868173 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S2764455111 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | PubMed Central |
| locations[2].source.host_organization | https://openalex.org/I1299303238 |
| locations[2].source.host_organization_name | National Institutes of Health |
| locations[2].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[2].license | other-oa |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | https://openalex.org/licenses/other-oa |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Ann Hematol |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/11868173 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5049210820 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Maximilian Fleischmann |
| authorships[0].affiliations[0].raw_affiliation_string | Comprehensive Cancer Center Central Germany, Campus Jena, Jena, Germany |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Maximilian Fleischmann |
| authorships[0].is_corresponding | True |
| authorships[0].raw_affiliation_strings | Comprehensive Cancer Center Central Germany, Campus Jena, Jena, Germany |
| authorships[1].author.id | https://openalex.org/A5065647464 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-2270-0804 |
| authorships[1].author.display_name | Madlen Jentzsch |
| authorships[1].affiliations[0].raw_affiliation_string | Comprehensive Cancer Center Central Germany, Campus Leipzig, Leipzig, Germany |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Madlen Jentzsch |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Comprehensive Cancer Center Central Germany, Campus Leipzig, Leipzig, Germany |
| authorships[2].author.id | https://openalex.org/A5030849615 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-4072-7592 |
| authorships[2].author.display_name | Annamaria Brioli |
| authorships[2].countries | DE |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I2799318839 |
| authorships[2].affiliations[0].raw_affiliation_string | Klinik Und Poliklinik für Innere Medizin C, Abteilung für Hämatologie Und Onkologie, Universitätsklinikum Greifswald, Greifswald, Germany |
| authorships[2].institutions[0].id | https://openalex.org/I2799318839 |
| authorships[2].institutions[0].ror | https://ror.org/025vngs54 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I2799318839 |
| authorships[2].institutions[0].country_code | DE |
| authorships[2].institutions[0].display_name | Universitätsmedizin Greifswald |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Annamaria Brioli |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Klinik Und Poliklinik für Innere Medizin C, Abteilung für Hämatologie Und Onkologie, Universitätsklinikum Greifswald, Greifswald, Germany |
| authorships[3].author.id | https://openalex.org/A5010415339 |
| authorships[3].author.orcid | https://orcid.org/0009-0009-4305-5718 |
| authorships[3].author.display_name | Florian Eisele |
| authorships[3].countries | DE |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210126310 |
| authorships[3].affiliations[0].raw_affiliation_string | Medizinische Klinik Und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany |
| authorships[3].institutions[0].id | https://openalex.org/I4210126310 |
| authorships[3].institutions[0].ror | https://ror.org/03pvr2g57 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210126310 |
| authorships[3].institutions[0].country_code | DE |
| authorships[3].institutions[0].display_name | Universitätsklinikum Würzburg |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Florian Eisele |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Medizinische Klinik Und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany |
| authorships[4].author.id | https://openalex.org/A5085644179 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-1476-8059 |
| authorships[4].author.display_name | Jochen J. Frietsch |
| authorships[4].countries | DE |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210126310 |
| authorships[4].affiliations[0].raw_affiliation_string | Medizinische Klinik Und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany |
| authorships[4].institutions[0].id | https://openalex.org/I4210126310 |
| authorships[4].institutions[0].ror | https://ror.org/03pvr2g57 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210126310 |
| authorships[4].institutions[0].country_code | DE |
| authorships[4].institutions[0].display_name | Universitätsklinikum Würzburg |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Jochen J. Frietsch |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Medizinische Klinik Und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany |
| authorships[5].author.id | https://openalex.org/A5050059315 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Farina Eigendorff |
| authorships[5].countries | DE |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210134900 |
| authorships[5].affiliations[0].raw_affiliation_string | Klinik für Innere Medizin II, Abteilung für Hämatologie Und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany |
| authorships[5].institutions[0].id | https://openalex.org/I4210134900 |
| authorships[5].institutions[0].ror | https://ror.org/035rzkx15 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210134900 |
| authorships[5].institutions[0].country_code | DE |
| authorships[5].institutions[0].display_name | Jena University Hospital |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Farina Eigendorff |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Klinik für Innere Medizin II, Abteilung für Hämatologie Und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany |
| authorships[6].author.id | https://openalex.org/A5083622281 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | Romy Tober |
| authorships[6].countries | DE |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I4210134900 |
| authorships[6].affiliations[0].raw_affiliation_string | Klinik für Innere Medizin II, Abteilung für Hämatologie Und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany |
| authorships[6].institutions[0].id | https://openalex.org/I4210134900 |
| authorships[6].institutions[0].ror | https://ror.org/035rzkx15 |
| authorships[6].institutions[0].type | healthcare |
| authorships[6].institutions[0].lineage | https://openalex.org/I4210134900 |
| authorships[6].institutions[0].country_code | DE |
| authorships[6].institutions[0].display_name | Jena University Hospital |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Romy Tober |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Klinik für Innere Medizin II, Abteilung für Hämatologie Und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany |
| authorships[7].author.id | https://openalex.org/A5008761228 |
| authorships[7].author.orcid | https://orcid.org/0000-0003-2131-6779 |
| authorships[7].author.display_name | Karin G. Schrenk |
| authorships[7].countries | DE |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I4210134900 |
| authorships[7].affiliations[0].raw_affiliation_string | Klinik für Innere Medizin II, Abteilung für Hämatologie Und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany |
| authorships[7].institutions[0].id | https://openalex.org/I4210134900 |
| authorships[7].institutions[0].ror | https://ror.org/035rzkx15 |
| authorships[7].institutions[0].type | healthcare |
| authorships[7].institutions[0].lineage | https://openalex.org/I4210134900 |
| authorships[7].institutions[0].country_code | DE |
| authorships[7].institutions[0].display_name | Jena University Hospital |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Karin G. Schrenk |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Klinik für Innere Medizin II, Abteilung für Hämatologie Und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany |
| authorships[8].author.id | https://openalex.org/A5041733101 |
| authorships[8].author.orcid | |
| authorships[8].author.display_name | Jakob Hammersen |
| authorships[8].affiliations[0].raw_affiliation_string | Comprehensive Cancer Center Central Germany, Campus Jena, Jena, Germany |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Jakob Friedrich Hammersen |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Comprehensive Cancer Center Central Germany, Campus Jena, Jena, Germany |
| authorships[9].author.id | https://openalex.org/A5091805368 |
| authorships[9].author.orcid | |
| authorships[9].author.display_name | Olaposi Yomade |
| authorships[9].affiliations[0].raw_affiliation_string | Comprehensive Cancer Center Central Germany, Campus Jena, Jena, Germany |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Olaposi Yomade |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Comprehensive Cancer Center Central Germany, Campus Jena, Jena, Germany |
| authorships[10].author.id | https://openalex.org/A5044008964 |
| authorships[10].author.orcid | https://orcid.org/0000-0003-2038-9730 |
| authorships[10].author.display_name | Inken Hilgendorf |
| authorships[10].affiliations[0].raw_affiliation_string | Comprehensive Cancer Center Central Germany, Campus Jena, Jena, Germany |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Inken Hilgendorf |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Comprehensive Cancer Center Central Germany, Campus Jena, Jena, Germany |
| authorships[11].author.id | https://openalex.org/A5035964802 |
| authorships[11].author.orcid | https://orcid.org/0000-0003-0626-0834 |
| authorships[11].author.display_name | Andreas Hochhaus |
| authorships[11].countries | DE |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I4210134900 |
| authorships[11].affiliations[0].raw_affiliation_string | Klinik für Innere Medizin II, Abteilung für Hämatologie Und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany |
| authorships[11].institutions[0].id | https://openalex.org/I4210134900 |
| authorships[11].institutions[0].ror | https://ror.org/035rzkx15 |
| authorships[11].institutions[0].type | healthcare |
| authorships[11].institutions[0].lineage | https://openalex.org/I4210134900 |
| authorships[11].institutions[0].country_code | DE |
| authorships[11].institutions[0].display_name | Jena University Hospital |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Andreas Hochhaus |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Klinik für Innere Medizin II, Abteilung für Hämatologie Und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany |
| authorships[12].author.id | https://openalex.org/A5022644839 |
| authorships[12].author.orcid | https://orcid.org/0000-0003-2893-3630 |
| authorships[12].author.display_name | Sebastian Scholl |
| authorships[12].affiliations[0].raw_affiliation_string | Comprehensive Cancer Center Central Germany, Campus Jena, Jena, Germany |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Sebastian Scholl |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | Comprehensive Cancer Center Central Germany, Campus Jena, Jena, Germany |
| authorships[13].author.id | https://openalex.org/A5041262204 |
| authorships[13].author.orcid | https://orcid.org/0000-0001-7455-8988 |
| authorships[13].author.display_name | Ulf Schnetzke |
| authorships[13].affiliations[0].raw_affiliation_string | Comprehensive Cancer Center Central Germany, Campus Jena, Jena, Germany |
| authorships[13].author_position | last |
| authorships[13].raw_author_name | Ulf Schnetzke |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | Comprehensive Cancer Center Central Germany, Campus Jena, Jena, Germany |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1007/s00277-024-06048-5 |
| open_access.oa_status | hybrid |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-25T14:43:58.451035 |
| primary_topic.id | https://openalex.org/T10309 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2720 |
| primary_topic.subfield.display_name | Hematology |
| primary_topic.display_name | Acute Myeloid Leukemia Research |
| related_works | https://openalex.org/W4362592484, https://openalex.org/W4310159665, https://openalex.org/W3131716652, https://openalex.org/W4362542584, https://openalex.org/W4401878169, https://openalex.org/W2899412336, https://openalex.org/W4401875674, https://openalex.org/W4401979026, https://openalex.org/W4401504076, https://openalex.org/W4296614602 |
| cited_by_count | 1 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 1 |
| locations_count | 3 |
| best_oa_location.id | doi:10.1007/s00277-024-06048-5 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S163204731 |
| best_oa_location.source.issn | 0939-5555, 1432-0584 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 0939-5555 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Annals of Hematology |
| best_oa_location.source.host_organization | https://openalex.org/P4310319900 |
| best_oa_location.source.host_organization_name | Springer Science+Business Media |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310319900 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Annals of Hematology |
| best_oa_location.landing_page_url | https://doi.org/10.1007/s00277-024-06048-5 |
| primary_location.id | doi:10.1007/s00277-024-06048-5 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S163204731 |
| primary_location.source.issn | 0939-5555, 1432-0584 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 0939-5555 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Annals of Hematology |
| primary_location.source.host_organization | https://openalex.org/P4310319900 |
| primary_location.source.host_organization_name | Springer Science+Business Media |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310319900 |
| primary_location.license | cc-by |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Annals of Hematology |
| primary_location.landing_page_url | https://doi.org/10.1007/s00277-024-06048-5 |
| publication_date | 2024-10-25 |
| publication_year | 2024 |
| referenced_works | https://openalex.org/W3048827006, https://openalex.org/W3097974232, https://openalex.org/W4389234097, https://openalex.org/W4280515145, https://openalex.org/W3080879632, https://openalex.org/W3134215547, https://openalex.org/W3128822483, https://openalex.org/W4206238677, https://openalex.org/W4386271169, https://openalex.org/W4391464346, https://openalex.org/W3194828795, https://openalex.org/W4284884567, https://openalex.org/W4389975150, https://openalex.org/W4401504326, https://openalex.org/W1971888832, https://openalex.org/W1969684548, https://openalex.org/W2979469227, https://openalex.org/W2980911308, https://openalex.org/W4396770562, https://openalex.org/W4394725171, https://openalex.org/W4389734632, https://openalex.org/W4316591519, https://openalex.org/W4389802567, https://openalex.org/W4399519888, https://openalex.org/W4310108956, https://openalex.org/W4391982706, https://openalex.org/W3022969666, https://openalex.org/W4221058111, https://openalex.org/W4393183571, https://openalex.org/W4285728223, https://openalex.org/W4367173838, https://openalex.org/W4280583654, https://openalex.org/W4404099093, https://openalex.org/W4206979995, https://openalex.org/W4225753814 |
| referenced_works_count | 35 |
| abstract_inverted_index.9 | 76 |
| abstract_inverted_index.A | 59 |
| abstract_inverted_index.a | 148, 207 |
| abstract_inverted_index.(7 | 71 |
| abstract_inverted_index.11 | 78 |
| abstract_inverted_index.14 | 73 |
| abstract_inverted_index.15 | 176 |
| abstract_inverted_index.20 | 65 |
| abstract_inverted_index.In | 193 |
| abstract_inverted_index.No | 155 |
| abstract_inverted_index.OS | 171 |
| abstract_inverted_index.in | 101, 136, 158, 182, 189, 210 |
| abstract_inverted_index.is | 8, 32 |
| abstract_inverted_index.of | 3, 12, 54, 126, 138, 153, 184, 191, 218 |
| abstract_inverted_index.or | 72 |
| abstract_inverted_index.to | 48, 202, 221 |
| abstract_inverted_index.20% | 190 |
| abstract_inverted_index.55% | 183 |
| abstract_inverted_index.70% | 125 |
| abstract_inverted_index.75% | 137 |
| abstract_inverted_index.AML | 67 |
| abstract_inverted_index.The | 1, 90, 140 |
| abstract_inverted_index.age | 120 |
| abstract_inverted_index.all | 99 |
| abstract_inverted_index.and | 42, 52, 77, 88, 115, 166 |
| abstract_inverted_index.for | 14, 23, 172 |
| abstract_inverted_index.its | 27 |
| abstract_inverted_index.the | 10, 50, 164, 173, 216 |
| abstract_inverted_index.use | 31 |
| abstract_inverted_index.was | 62, 121, 134, 145, 175 |
| abstract_inverted_index.(OS) | 114 |
| abstract_inverted_index.2021 | 87 |
| abstract_inverted_index.73.5 | 122 |
| abstract_inverted_index.78%. | 154 |
| abstract_inverted_index.AML. | 130 |
| abstract_inverted_index.This | 45 |
| abstract_inverted_index.aims | 47 |
| abstract_inverted_index.bone | 107 |
| abstract_inverted_index.care | 13 |
| abstract_inverted_index.days | 74 |
| abstract_inverted_index.dose | 43 |
| abstract_inverted_index.four | 95 |
| abstract_inverted_index.from | 94 |
| abstract_inverted_index.rate | 143, 152 |
| abstract_inverted_index.risk | 133 |
| abstract_inverted_index.this | 194 |
| abstract_inverted_index.were | 161, 180 |
| abstract_inverted_index.with | 5, 17, 35, 75, 82, 124, 147, 186, 206 |
| abstract_inverted_index.(AML) | 21 |
| abstract_inverted_index.(ORR) | 144 |
| abstract_inverted_index.100%, | 146 |
| abstract_inverted_index.2024. | 89 |
| abstract_inverted_index.7-day | 165 |
| abstract_inverted_index.These | 213 |
| abstract_inverted_index.acute | 18 |
| abstract_inverted_index.adult | 66 |
| abstract_inverted_index.days) | 85 |
| abstract_inverted_index.first | 102 |
| abstract_inverted_index.line. | 103 |
| abstract_inverted_index.often | 33 |
| abstract_inverted_index.rates | 160 |
| abstract_inverted_index.study | 46 |
| abstract_inverted_index.while | 225 |
| abstract_inverted_index.(5–7 | 84 |
| abstract_inverted_index.(PFS). | 118 |
| abstract_inverted_index.14-day | 167 |
| abstract_inverted_index.German | 96 |
| abstract_inverted_index.Median | 119, 170 |
| abstract_inverted_index.agents | 7 |
| abstract_inverted_index.cases. | 192 |
| abstract_inverted_index.cohort | 91, 174 |
| abstract_inverted_index.delays | 41 |
| abstract_inverted_index.having | 128 |
| abstract_inverted_index.marrow | 108 |
| abstract_inverted_index.safety | 53 |
| abstract_inverted_index.sepsis | 188 |
| abstract_inverted_index.severe | 187 |
| abstract_inverted_index.years, | 123 |
| abstract_inverted_index.Adverse | 131 |
| abstract_inverted_index.Despite | 26 |
| abstract_inverted_index.Outcome | 104 |
| abstract_inverted_index.adverse | 228 |
| abstract_inverted_index.between | 86, 163 |
| abstract_inverted_index.centers | 98 |
| abstract_inverted_index.cohort, | 195 |
| abstract_inverted_index.elderly | 15 |
| abstract_inverted_index.months. | 177 |
| abstract_inverted_index.myeloid | 19 |
| abstract_inverted_index.overall | 112, 141 |
| abstract_inverted_index.support | 215 |
| abstract_inverted_index.treated | 100 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.academic | 97 |
| abstract_inverted_index.analysis | 61 |
| abstract_inverted_index.clinical | 30, 223 |
| abstract_inverted_index.combined | 81 |
| abstract_inverted_index.complete | 150 |
| abstract_inverted_index.effects. | 229 |
| abstract_inverted_index.efficacy | 51, 200 |
| abstract_inverted_index.evaluate | 49 |
| abstract_inverted_index.findings | 214 |
| abstract_inverted_index.included | 92, 106 |
| abstract_inverted_index.leukemia | 20 |
| abstract_inverted_index.measures | 105 |
| abstract_inverted_index.observed | 135, 162, 181 |
| abstract_inverted_index.optimize | 222 |
| abstract_inverted_index.outcomes | 224 |
| abstract_inverted_index.patients | 16, 68, 93, 127 |
| abstract_inverted_index.regimens | 198, 220 |
| abstract_inverted_index.response | 142, 159 |
| abstract_inverted_index.standard | 11, 203 |
| abstract_inverted_index.survival | 113, 117 |
| abstract_inverted_index.composite | 149 |
| abstract_inverted_index.conducted | 63 |
| abstract_inverted_index.currently | 9 |
| abstract_inverted_index.efficacy, | 29 |
| abstract_inverted_index.favorable | 28 |
| abstract_inverted_index.intensive | 24 |
| abstract_inverted_index.involving | 64 |
| abstract_inverted_index.molecular | 132 |
| abstract_inverted_index.patients, | 79, 185 |
| abstract_inverted_index.patients. | 139 |
| abstract_inverted_index.potential | 208 |
| abstract_inverted_index.receiving | 69 |
| abstract_inverted_index.reduction | 209 |
| abstract_inverted_index.regimens. | 169 |
| abstract_inverted_index.remission | 151 |
| abstract_inverted_index.response, | 109 |
| abstract_inverted_index.secondary | 129 |
| abstract_inverted_index.shortened | 55, 196 |
| abstract_inverted_index.toxicity. | 212 |
| abstract_inverted_index.treatment | 40, 57, 204, 219 |
| abstract_inverted_index.associated | 34 |
| abstract_inverted_index.comparable | 201 |
| abstract_inverted_index.cytopenia, | 37 |
| abstract_inverted_index.durations. | 58 |
| abstract_inverted_index.frequently | 38 |
| abstract_inverted_index.ineligible | 22 |
| abstract_inverted_index.minimizing | 227 |
| abstract_inverted_index.protocols, | 205 |
| abstract_inverted_index.venetoclax | 4, 56, 70, 168, 197 |
| abstract_inverted_index.combination | 2 |
| abstract_inverted_index.dependence, | 111 |
| abstract_inverted_index.differences | 157 |
| abstract_inverted_index.hematologic | 211 |
| abstract_inverted_index.multicenter | 60 |
| abstract_inverted_index.potentially | 226 |
| abstract_inverted_index.significant | 156 |
| abstract_inverted_index.transfusion | 110 |
| abstract_inverted_index.demonstrated | 199 |
| abstract_inverted_index.5-azacitidine | 83 |
| abstract_inverted_index.chemotherapy. | 25 |
| abstract_inverted_index.complications | 179 |
| abstract_inverted_index.necessitating | 39 |
| abstract_inverted_index.respectively) | 80 |
| abstract_inverted_index.modifications. | 44 |
| abstract_inverted_index.post-remission | 36 |
| abstract_inverted_index.hypomethylating | 6 |
| abstract_inverted_index.progression-free | 116 |
| abstract_inverted_index.Infection-related | 178 |
| abstract_inverted_index.individualization | 217 |
| cited_by_percentile_year.max | 95 |
| cited_by_percentile_year.min | 91 |
| corresponding_author_ids | https://openalex.org/A5049210820 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 14 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8299999833106995 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.73173281 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |